VEGZELMA 25 mg/mL concentrate for solution for infusion
Sponsors
Janssen Cilag International, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Academisch Ziekenhuis Maastricht, Daiichi Sankyo Inc.
Conditions
KRAS/NRAS and BRAF Wildtype RecurrentMetastatic colorectal cancerOvarian CancerPatients with metastatic non-squamous NSCLC pre-treated with platinum-doublet chemotherapy and ICI (for those with targetable oncogenic driversUnresectable or Metastatic Colorectal Cancerand active BMdefined as asymptomatic untreated or unequivocally progressive after local treatmentpretreated with at least one tyrosine kinase inhibitor and platinum-doublet chemotherapy)
Phase 2
Sequential immunochemotherapy treatment with Pembrolizumab plus Dendritic Cell (DC) Vaccine followed by Trifluridine/Tipiracil plus Bevacizumab in refractory mismatch-repair-proficient (pMMR) or microsatellite-stable (MSS) metastatic colorectal cancer
RecruitingCTIS2024-514053-30-00
Start: 2025-01-07Target: 36Updated: 2024-11-07
A single arm phase II study evaluating intracranial efficacy of Sacituzumab govitecan (SG) with bevacizumab in patients with asymptomatic brain metastases from non-small cell lung cancer (NSCLC)
RecruitingCTIS2024-514066-40-00
Start: 2025-07-10Target: 25Updated: 2025-03-17
Phase 3
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus
Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype
Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior
Chemotherapy
RecruitingCTIS2024-513853-66-00
Start: 2025-02-04Target: 162Updated: 2026-01-07
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Verus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112)
RecruitingCTIS2024-516982-35-00
Start: 2025-09-11Target: 182Updated: 2026-01-21